The estimated Net Worth of Donald William Nicholson is at least $9.56 Milión dollars as of 1 December 2023. Donald Nicholson owns over 100,000 units of Kymera Therapeutics stock worth over $9,561,798 and over the last 4 years Donald sold KYMR stock worth over $0.
Donald has made over 3 trades of the Kymera Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently Donald bought 100,000 units of KYMR stock worth $144,000 on 1 December 2023.
The largest trade Donald's ever made was buying 100,000 units of Kymera Therapeutics stock on 1 December 2023 worth over $144,000. On average, Donald trades about 9,542 units every 88 days since 2020. As of 1 December 2023 Donald still owns at least 213,576 units of Kymera Therapeutics stock.
You can see the complete history of Donald Nicholson stock trades at the bottom of the page.
Donald's mailing address filed with the SEC is C/O GENERATION BIO CO., 301 BINNEY ST, , CAMBRIDGE, MA, 02142.
Over the last 4 years, insiders at Kymera Therapeutics have traded over $179,227,903 worth of Kymera Therapeutics stock and bought 2,497,406 units worth $70,844,455 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Bros. Advisors Lp667, L.P.B... a Group, Llc Green Jeremy Red.... On average, Kymera Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,989,455. The most recent stock trade was executed by Jeffrey W. Albers on 26 August 2024, trading 5,000 units of KYMR stock currently worth $51,700.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics executives and other stock owners filed with the SEC include: